M0 acute myeloid leukemia (M0-AML)

2002-05-01   Marie Christine Bene 

1.Laboratoire dImmunologie du CHU, Faculté de Médecine de Nancy, BP 184, 54500 Vandoeuvre les Nancy, France
2.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Clinics and Pathology

Epidemiology

rare: 3 - 5 % of AML; med age 45 yrs; 20% are children; unbalanced sex ratio in the adults: 1.6 M/1F, p< 0.01

Clinics

High WBC mostly in children; frequently low Hb and platelets; organomegaly in children

Cytology

Undifferentiated blasts, cytochemistry: negative for myeloperoxydase. Positivity of at least one myeloid marker (CD13, CD33, CD65, CD117-c-KIT). Frequent expression of early progenitor markers CD34, DR; TdT in 30-40% of the cases; CD7 expression frequent in children. MPO antigen identified in about 50% of the cases.

Prognosis

Poor: CR in 50% of cases, med survival: 8 mths Poor prognosis factors: older age, high WBC, low platelets, CD10, CD14, CD15.

Bibliography

Pubmed IDLast YearTitleAuthors
113804652001Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients.Béné MC et al
105167511999The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors.Costello R et al
103895941999AML-M0: a review of laboratory features and proposal of new diagnostic criteria.Stasi R et al

Summary

Note

Stasis criteria
  • 30% blast cells in the bone marrow with

    • Citation

    Marie Christine Bene

    M0 acute myeloid leukemia (M0-AML)

    Atlas Genet Cytogenet Oncol Haematol. 2002-05-01

    Online version: http://atlasgeneticsoncology.org/haematological/1057/m0anllid1057

    Historical Card

    1999-12-01 M0 acute myeloid leukemia (M0-AML) by  Jean-Loup Huret 

    Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France